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de Recerca i Estudis Avançats, Catalonia, SpainHepatocellular carcinoma (HCC) is a deadly cancer, whose inci- consolidation of sophisticated animal models, such as mosaic can-
dence is increasing worldwide. Albeit the main risk factors for
HCC development have been clearly identiﬁed, such as hepatitis
B and C virus infection and alcohol abuse, there is still prelimin-
ary understanding of the key drivers of this malignancy. Recent
data suggest that genomic analysis of cirrhotic tissue – the pre-
neoplastic carcinogenic ﬁeld – may provide a read-out to identify
at risk populations for cancer development. Given this contextual
complexity, it is of utmost importance to characterize the molec-
ular pathogenesis of this disease, and pinpoint the dominant
pathways/drivers by integrative oncogenomic approaches and/
or sophisticated experimental models. Identiﬁcation of the dom-
inant proliferative signals and key aberrations will allow for a
more personalized therapy.
Pathway-based approaches and functional experimental stud-
ies have aided in identifying the activation of different signaling
cascades in HCC (e.g. epidermal growth factor, insulin-like growth
factor, RAS,MTOR,WNT-bcatenin, etc.). However, the introduction
of new high-throughput genomic technologies (e.g. microarrays,
deep sequencing, etc.), and increased sophistication of computa-
tional biology (e.g. bioinformatics, biomodeling, etc.), opens the
ﬁeld to new strategies in oncogene and tumor suppressor discov-
ery. These oncogenomic approaches are framed within emerging
newdisciplines such as systemsbiology,which integratesmultiple
inputs to explain cancer onset and progression. In addition, theJournal of Hepatology 20
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screens, have been instrumental for the identiﬁcation of novel
tumor drivers. We herein review some classical as well as some
recent fast track approaches for oncogene discovery in HCC, and
provide a comprehensive landscape of the currently known spec-
trum of molecular aberrations involved in hepatocarcinogenesis.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Overview
Hepatocellular carcinoma (HCC) represents a major health prob-
lem worldwide [1]. Despite its global importance, liver cancer is
understudied compared to other major lethal cancers, and hence,
our knowledge of the genomic alterations implicated in HCC ini-
tiation and progression is still fragmentary. This is partly due to
the high complexity and heterogeneity of HCC cancer genomes,
which hamper a straightforward identiﬁcation of new cancer
genes by genomic approaches alone. There is also only a limited
arsenal of model systems available to study the development of
the disease, and to test potential intervention strategies. In this
scenario, HCC is probably one of the tumor types where a more
complete understanding of the underlying genetic alterations
could have a major impact on the development of new treatment
strategies. Because of their therapeutic relevance as potential
new targets, this review will ﬁrst summarize the current knowl-
edge of signaling pathways in HCC. Next, we will brieﬂy comment
the role of P53 due to its paradigmatic role as a tumor suppressor
in HCC, identiﬁed using a gene-based approach. Finally, we will
discuss new integrative oncogenomic approaches for an acceler-
ated cancer gene discovery in HCC.Signaling pathways in hepatocellular carcinoma
Activation of several signaling pathways, both in cirrhotic tissue
and in overt HCC, has been implicated in human hepatocarcino-
genesis [2] (Fig. 1). Their relevance resides in their capacity to
act as targets for new therapies. In fact, activation of RAS/MAPK
and VEGF signaling (i.e. angiogenesis) in HCC stimulated initial10 vol. 52 j 921–929
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evaluations of the multi-kinase inhibitor sorafenib for the treat-
ment of human HCC. As a result of recent positive investigations,
sorafenib is currently the sole systemic therapy approved for the
treatment of advanced HCC [3,4].
Proliferation signaling pathways
Epidermal growth factor (EGF) signaling is one of the most thor-
oughly evaluated signaling cascades in human HCC. Robust data
demonstrate its activation in a subset of HCC, up-regulation of
EGF being one of its mechanisms of activation [5]. Genetic evi-
dence was also provided by a recent study showing gains of chro-
mosome 7 in human HCC, where EGFR is located [6]. Some
complementary evidence points to EGF as a key driver in HCC.
A case-control study identiﬁed a signiﬁcant increase in HCC risk
associated with a speciﬁc single nucleotide polymorphism
(SNP) of the EGF gene [7]. Interestingly, the same investigation
showed that this SNP increased EGF mRNA stability in cell lines;
thus, markedly enhancing signaling through the EGF receptor
(EGFR). Additionally, EGF was ranked among the top up-regu-
lated genes included in a gene signature that was able to identify
HCC patients treated with surgical resection at high risk of devel-
oping a late recurrence (de novo HCC) [8]. Unsupervised muta-
genic screening in mice also detected EGFR as a relevant gene
during HCC development [9]. There are some consistent data
regarding a selective EGF-blockade in experimental models. Gef-
itinib, an EGFR tyrosine kinase inhibitor, was able to signiﬁcantly
decrease HCC incidence in a genotoxic model of HCC [10].
Another study showed anti-proliferative and pro-apoptoticTumor Development
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In addition, robust evidence suggests the prominent role of TGFA
as a major paracrine activator of EGF signaling in HCC [11]. TGFA
contributes to proliferation and the invasion phenotype of tumor
cells, and it has been shown to generate liver tumors upon co-
activation with other oncogenes in animal models [e.g. double-
transgenic mice: MYC/TGFA [12]. Finally, preliminary data
obtained in phase II clinical trials using an EGFR speciﬁc inhibitor
(i.e. erlotinib) in HCC [13,14], are currently being expanded into
phase III investigations.
The insulin-like growth factor (IGF) signaling system is an
essential regulator of growth and development [15]. The biolog-
ical actions of the axis comprise a complex network of molecules
whose main components are two high-afﬁnity mitogenic ligands:
IGF1 and IGF2. The type 1 IGF receptor (IGF1R) has tyrosine
kinase activity, the type 2 IGF receptor (IGF2R) is involved in
the internalization and degradation of IGF2, and at least six
high-afﬁnity IGF–binding proteins (IGFBPs) which modulate the
amount and bioactivity of locally available IGFs. Despite its role
in normal physiology, the IGF axis is involved in the pathogenesis
of several human malignancies, including breast, colon, prostate,
lung, and liver [16]. In HCC, the most frequently described aber-
rant feature concerning this pathway is over-expression of IGF2,
even found in pre-neoplastic lesions [11]. This mitogen, highly
expressed during embryonic development, is strongly down-reg-
ulated after birth due to tight epigenetic regulation of the P2-P4
fetal promoters. Reactivation of IGF2 expression involves loss of
speciﬁc imprinting and hypomethylation [17]. Allelic losses of
IGF2R have been detected in 60–70% of HCC, being inactivatingTumor Progression
and Invasion
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mutations in the remaining allele also reported [18]. In addition,
reduced expression of IGFBP-3 associated to promoter hyperme-
thylation has been reported in human HCC samples [19]. A recent
study found aberrant activation of IGF1R in 21% of early stage
hepatitis C-related HCC, and provided preclinical evidence of
antineoplastic activity following IGF1R selective blockade using
a monoclonal antibody [20]. The potential role of the HBx viral
protein as an inducer of IGF-IR expression has been also sug-
gested [21].
Hepatocyte growth factor (HGF) is a potent mitogen for hepa-
tocytes, and the unique ligand for the MET receptor. MET activa-
tion by HGF induces disruption of intercellular links and allows
cells to migrate from their primary location to adjacent surround-
ings. The HGF/MET system is a major player of cell migration dur-
ing embryogenesis and recent data has shown that the HGF/MET
system is involved in reactivation of the ‘‘invasive program” dur-
ing tumor progression and metastasis [22]. In addition, inhibition
of MET expression using RNA-interference in cancer cell lines
harboring MET ampliﬁcations decreased cell proliferation, sur-
vival, and invasion as well as delayed tumor growth in xenograft
models [23]. MET activation in cancer may occur by several
mechanisms including ligand-receptor autocrine stimulation,
somatic and germ-line mutations, or MET ampliﬁcation, allowing
MET activation even in the absence of HGF [24].
In HCC, several investigators identiﬁed over-expression of
MET (20–48%) when compared to surrounding non-tumoral tis-
sue. For example, a study found a correlation between MET
over-expression and a higher incidence of intrahepatic metasta-
ses, as well as a reduced survival following tumor resection
[25]. By contrast, decreased HGF expression has been reported
in HCC [25], suggesting a marginal role for HGF in this malig-
nancy. A recent study took advantage of a comparative functional
genomics approach on 242 HCC samples for identifying a gene
signature correlated with HCC metastatic potential. This signa-
ture included genes associated with oxidative stress, cell motility,
cytoskeletal organization, and angiogenesis [26]. Overall, MET
has emerged as a very attractive target for anticancer therapies,
albeit there is no approved drug so far. Moreover, there is com-
pelling evidence of anti-neoplasic activity (i.e. decreased prolifer-
ation, migration and invasion) following MET down-regulation in
experimental models of HCC [27].
Upon EGFR, IGFR or MET activation, extracellular signals can
be transduced through either AKT or MAPK signaling pathways.
Molecules belonging to both signaling cascades (e.g. AKT or
KRAS) have been identiﬁed as bona ﬁde oncogenes in human can-
cer. The RAS cascade transduces extracellular signals initiated by
growth factor receptor activation that in turn activate RAF, MEK
and ERK and result in proliferative and anti-apoptotic signals
[28]. RAS mutations in HCC are found at low frequency [29].
Interestingly, recent studies show frequent over-expression of
RAS in human HCC [30,31]. In addition, down-regulation of RAS
negative regulators has been reported, such as hypermethylation
of the RAS association family 1 gene A (RASSF1A) and its homo-
logue NORE1A [30]. There is no pure anti-RAS therapy approved,
and only sorafenib has shown some effective signaling blockage,
either alone or in combination with rapamycin (RAS and MTOR
blockade in experimental models) [31].
AKT has been described as a predictor of tumor recurrence
after surgical resection in a large cohort of Japanese patients
[32], suggesting a possible implication in the invasive phenotype.
MTOR is one of the most important molecules downstream AKT.Journal of Hepatology 201Two distinct MTOR complexes have been described, one closely
implicated in protein translation, mTOR complex 1 (MTORC1),
whereas the other, mTOR complex 2 (MTORC2), is the primary
one responsible for the phosphorylation of AKT at serine 473,
conferring its full activation [33]. There are intriguing feedback-
loops in the mTOR pathway, which partly explains why the exact
implications of each MTOR complex in the molecular pathogene-
sis of cancer are not fully understood [34]. However, it seems that
MTORC2 integrity could be necessary to sustain the oncogenic
phenotype related to the loss of PTEN, at least in prostate cancer
[35]. As recently reported, MTORC1 plays a pivotal role in human
HCC [5]. Evidence from different studies has demonstrated
MTORC1 activation in a subset of HCC patients, showing prognos-
tic implications for some of them in terms of patient tumor recur-
rence after surgery [5]. Moreover, the anti-neoplasic properties of
MTOR inhibitors (e.g. rapamycin and its analogs) in experimental
models of HCC further increase the relevance of this pathway
[36]. All this compiled evidence established the proof-of-princi-
ple to conduct clinical trials evaluating mTOR inhibitors in
human HCC.Pathways involved in liver development and cell differentiation
The ultimate identity of the speciﬁc target cell for transforma-
tion in HCC is still elusive [37]. Despite recent progresses, the
involvement of altered embryonic cellular features such as
self-renewal, plasticity, asymmetric division, pluripotency and
cellular fate in human cancer remains enigmatic [38]. In accor-
dance with the cancer stem cell hypothesis, a number of stud-
ies found dysregulation of pathways involved in cellular
differentiation in HCC, such as the WNT canonical pathway.
Besides its role in liver development and differentiation
[39,40], WNT signaling has also been implicated in cell prolif-
eration and metabolism [41]. Unlike colon cancer, APC muta-
tions are infrequent in HCC, whereas CTNNB1 and AXIN1
mutations are frequently found in HCC [2]. Mutations prevent
b-catenin ubiquitination and subsequent degradation. Nuclear
accumulation of b-catenin induces transcription of several
genes related to cell differentiation and proliferation. In addi-
tion, unsupervised clustering of gene expression data from
two different studies enabled the identiﬁcation of a subclass
of patients characterized by activation of genes related to
WNT signaling [6,42]. Hence, there is enough evidence to
assume the implication of this signaling cascade in HCC,
although it is still unknown whether non-canonical activation
of this pathway may also be relevant during human hepatocar-
cinogenesis. There are currently several efforts evaluating dif-
ferent blockade strategies for the WNT pathway, stabilization
of AXIN being one of the most promising [43]. Nevertheless,
there are no clinical trials in late phases evaluating selective
blockade of any of its components.
Another pathway involved in proliferation control that is
found abnormally activated in HCC is the Hedgehog signaling
pathway (HH). This cascade is structurally very similar to WNT,
although different mechanisms account for the dysregulation of
HH. Over-expression of Sonic or Indian ligands, and/or inactiva-
tion of a tumor suppressor, the HH inhibitory protein, have been
identiﬁed as responsible for HH activation in experimental mod-
els of HCC as well as in human samples [44,45]. Several HH inhib-
itors are currently under preclinical evaluation in HCC.0 vol. 52 j 921–929 923
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Pathways involved in inﬂammation
The role of cascades involved in inﬂammation has been described
in early stages of the disease. Inﬂammation is a hallmark of liver
cirrhosis, and hence, several inﬂammation-related pathways have
been evaluated as potential targets for HCC chemoprevention. In a
recent large clinical study (n = 1005), anti-viral therapies with
interferon failed to show efﬁcacy in terms of HCC-prevention in
patients with hepatitis C-related liver disease who did not
respond to conventional anti-viral therapies [46]. Nonetheless,
other information pinpoints interleukin-6 (IL-6) signaling as an
appealing target for HCC-prevention. IL-6, a multifunctional cyto-
kine with different functions in the immune system, justiﬁes gen-
der disparities in HCC incidence (i.e. much higher incidence rate in
males than females [47]). Estrogens suppress IL-6 production and
therefore limit chemically induced liver carcinogenesis.
Enrichment in IL-6 downstream signals has also been found in
a gene signature associated with poor survival and de novo tumor
formation in patients with HCC treated with surgical resection
[8]. Additionally, a recent report identiﬁed IL-6 signaling through
STAT3 as a major pathway in maintaining stem cell like features
in HCC [48], highlighting the potential role of this cascade as a
novel target in cancer stem cell renewal. Currently, different
anti-IL-6 humanized monoclonal antibodies are under evaluation
in inﬂammatory conditions, but their role in HCC is yet to be
determined. There is some degree of crosstalk between IL-6 and
TGFB signaling, a pleiotropic pathway with potentially antagonis-
tic actions. Comparative functional genomics have allowed the
identiﬁcation of a subgroup of HCC patients with a signiﬁcant
enrichment in late responsive TGFB genes. Thus patients express-
ing these genes also had more invasive tumors and poor survival
[49]. All these data have encouraged efforts aiming to modulate
TFGB signaling, in part due to its clear involvement in metastasis.
Downstream of IL-6, signals can be transduced through the JAK/
STAT signaling cascade. Nuclear localization of STAT3 results in
trans-activation of its target genes (e.g. protein inhibitors of acti-
vated STATS [PIAS], the SH2-containing phosphatases [SHP], and
the suppressors of cytokine signaling [SOCS]), implicated in cell
growth, proliferation, differentiation and survival. Constitutive
activation of JAK/STAT has been detected in a subset of HCC,
mostly due to promoter methylation of STAT inhibitors such as
CIS, SOCS-1, SOCS-2, SOCS-3, and SHP1 [30]. Additionally, treat-
ment with de-methylating agents resulted in growth suppression
and strongly induced apoptosis in HCC cell lines [30].
There is strong evidence suggesting a linking role of the NF-
Kappab cascade in inﬂammation and liver oncogenesis [50].
Recent progress regarding drug-mediated inhibition of this path-
way provides new perspectives for primary prevention strategies
in cirrhotic patients. AEG1 has been identiﬁed as a downstream
molecule in this pathway, and could also act as a novel molecular
target in this setting [51]. Additionally, aberrant activation of the
lymphotoxin pathway in mice livers recapitulates the stages of
ﬁbrosis and inﬂammation that precedes human liver cancer, pro-
viding a novel family of potential therapeutic targets [52,53].
Pathways involved in neoangiogenesis
High vascularization is a hallmark of human HCC. Tumor cells
release pro-angiogenic factors in response to hypoxic conditions
and nutrient deprivation and thus activate endothelial cells. Mul-
tiple preclinical studies have revealed vascular endothelial924 Journal of Hepatology 201growth factor (VEGF), and ﬁbroblast growth factors (FGFs) as
major drivers underlying pro-angiogenic signals in human HCC.
VEGF is considered the most potent angiogenic factor in HCC,
and it is often found over-expressed in tumor specimens, as well
as its receptors VEGFR-1 and VEGFR-2. Moreover, high VEGF
expression levels have been consistently associated with a more
aggressive disease [54], and VEGF serum levels have also been
identiﬁed as a predictor of poor prognosis after resection [55].
The FGF receptor family includes 4 transmembrane receptors
(FGF1-4) and 1 soluble receptor (FGF5) and at least 23 known
ligands. There is evidence that links FGF signaling dysregulation
and malignant transformation of several cancers. In HCC, clinical
studies have shown over-expression of FGFs in human samples
and correlation with tumor angiogenesis [56]. Several studies
have reported crosstalk between FGF and VEGF signaling, indicat-
ing a possible synergistic effect of both cascades promoting angi-
ogenesis [57]. Besides these pathways, angiopoetins (Ang) have
also been involved in normal and aberrant vascular formation
through its interaction with the receptor Tie-2. Despite recent
controversial data, Ang-2 has been described as a promoter of
tumor angiogenesis in HCC, particularly in the presence of VEGF
[58]. Finally, experimental models have suggested a role for
another pro-angiogenic cascade, platelet derived growth factor
(PDGF) signaling, in HCC development [59]. Indeed, PDGF recep-
tor C transgenic mice developed ﬁbrosis and HCC with long
latency [60]. Results of the recently published phase III clinical
trial with sorafenib (i.e. B-Raf, VEGFR and PDGFR inhibitor) fur-
ther suggest an important role of anti-angiogenic agents in the
therapeutic management of HCC [4].
The P53 tumor suppressor
The P53 tumor suppressor has been found mutated in more than
50% of all human tumors. Owing to its role in preserving genetic
stability, P53 was designated as the guardian of the genome.
Upon DNA damage inducing cellular stresses, P53 becomes acti-
vated and prevents further damage and oncogenic transforma-
tion by either triggering apoptosis or by inducing a transient
cell cycle arrest to allow DNA repair [61]. The p53 protein is a
tetrameric transcription factor, and, in addition to its roles in
apoptosis- and cell cycle regulation, P53 was shown to impact
cellular differentiation, developmental processes and senes-
cence. Over the past couple of years it was shown that P53 plays
a major role in hepatocarcinogenesis. Strikingly, there is a high
variability in the frequency of P53 mutations and its mutational
spectrum in different geographical areas. In areas with high
Aﬂatoxin B1 food contamination (sub-Saharan Africa and China)
there is a high percentage of HCCs revealing a recurrent point
mutation at the third position of codon 249 resulting in a G:C
to T:A transversion [62]. Interestingly, it was shown that the
249Ser mutation is an early event in AFB1-induced hepatocarci-
nogenesis, with a high frequency of 249Ser mutations already
being found in non-tumoral regions of livers with chronic
AFB1 exposure [62]. In strong contrast, P53 mutations are
believed to represent a late, progression-associated event in
hepatocarcinogenesis in non-AFB1 related HCCs. For example,
different P53 mutations have been found in nodules in HCCs
leading to disease progression, and overall P53 mutations are
preferentially found in less differentiated HCCs. One major risk
factor for the development of hepatocellular carcinoma is
chronic infection with hepatotropic viruses like hepatitis B and0 vol. 52 j 921–929
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C. Different viral proteins have been shown to impact hepatocar-
cinogenesis in experimental systems. In the past couple of years,
a lot of attention was paid to the hepatitis B virus X protein
(HBx), one of the most frequently integrated viral genes in the
host genome [63,64]. Besides many other functions, HBx was
shown to bind P53 and to block P53 sequence speciﬁc
DNA-binding and P53 dependent transcription, being ultimately
capable of blocking P53-mediated apoptosis.Cancer genome screening and validation strategies
Current efforts in cancer gene discovery mostly rely on genomic
approaches alone. Recent advances in genome scanning technol-
ogies have enabled to examine cancer genomes at a high-resolu-
tion, thus making it feasible to catalogue every gene whose
mutation occurs in human cancer [65]. Regions of copy number
alteration can be identiﬁed by high-resolution array-based com-
parative genomic hybridization (CGH) or SNP arrays. Regions of
chromosomal ampliﬁcation mostly harbor oncogenes whereas
deleted regions contain tumor suppressor genes [66]. In addition,
high-throughput sequencing technologies are available for detec-
tion of somatic point mutations selected during tumor evolution
[67,68]. However, such approaches are expensive and yield can-
didates based on statistical criteria only. The situation is even
more complicated because due to genomic instability, gene link-
age and spontaneous mutagenesis, cancers also contain many
passenger mutations that are not contributing to the tumor phe-
notype. Moreover, it is difﬁcult to pinpoint relevant tumor sup-
pressors in large deletions, as some genes are haploid sufﬁcient
tumor suppressors, so that loss of even one allele can promote
tumorigenesis, even without a corresponding mutation in the
remaining wild-type allele. In conclusion, candidate genes identi-
ﬁed through genomic approaches require stringent functional
validation before expensive drug development efforts can be jus-
tiﬁed. In this regard, functional characterization of cancer genes is
often a tedious process, and it is not always obvious which assays
will reveal the putative oncogenic activity of a previously unchar-
acterized gene. Furthermore, although cell culture systems are
fast and tractable, they do not recapitulate important factors like
the tumor microenvironment, and consequently, they do not
allow surveying all relevant gene activities.
For proving new candidate cancer genes it has become gold
standard to generate transgenic and knockout mice, and to study
the respective genes in a relevant context in vivo [69]. Impor-
tantly, as such genetically engineered mouse models (GEMM)
allow to generate a detailed map of the route taken by the tumor
cell to reach its destination, cancer mouse models are suitable for
modeling intermediate stages of tumor formation, which is
essential for a complete understanding of the disease and for
the development of new treatment strategies. This is in strong
contrast to the traditional studies of human cancers, which only
provide a snapshot of the ﬁnal result. GEMM also play an impor-
tant role in preclinical drug testing, as it is becoming more evi-
dent that subcutaneously grown tumors in immunodeﬁcient
mice, which were derived from cultured tumor cell lines, may
not predict the treatment responses of human tumors, and may
hence contribute to the high numbers of ineffective compounds
entering clinical trials [70].
Over the last years, GEMM have provided elegant and power-
ful approaches to validate potential oncogene and tumor sup-Journal of Hepatology 201pressor genes in HCC (Table 1A) [12,60,71–90]. Currently,
mouse models of liver cancer are based mainly on classic trans-
genic approaches, tetracycline-regulated transgene expression
or chemically induced carcinogenesis (thoroughly reviewed else-
where [91]). These models have provided important insights into
the molecular mechanisms of hepatocarcinogenesis, although,
they have several limitations. First, the use of tissue-speciﬁc pro-
moters generates a bias towards certain epithelial cells and may
thus alter the cell of origin. Furthermore, the homogeneous
expression of an oncogene (or deletion of a tumor suppressor
gene) in all cells within a tissue creates a ﬁeld effect such that
all cells have altered gene expression, a situation that clearly does
not mimic the situation of spontaneous tumorigenesis in
humans. Secondly, it is very cost and time-intensive to generate
germ-line transgenic and knockout animals, and production of
compound mutant animals can involve complicated intercrossing
strategies that are extremely slow. Thirdly, germ-line transmis-
sion of transgenes or targeted knock-out alleles in some cases
produce prenatal abnormalities resulting in embryonic lethality
or developmental compensation in the resulting tissue.
A strategy that addresses some of the problems with germ-
line transgenic mice is the use of so called chimeric mouse
models, which are based on the genetic manipulation and
retransplantation of stem or progenitor cells. Such models were
initially developed for studying hematopoietic malignancies and
have proven very successful to get new insights into mechanisms
of tumor initiation, progression and treatment response in blood
cancer [92–95]. More recently such models were also developed
for the study of HCC [73,96]; these mosaic HCC mouse models are
based on the ex-vivo manipulation of liver progenitor cells fol-
lowed by the seeding of these cells into normal recipients. They
allow studying compound genetic lesions in HCC at a fraction
of the time that would be needed when using standard transgenic
or knockout approaches.
Integrative oncogenomic approaches for accelerated cancer
gene discovery in HCC
To speed up the process of cancer gene discovery in HCC, recent
studies took advantage of integrative approaches, where onco-
genomic analyses of human HCC were coupled with screening
approaches in innovative mosaic cancer mouse models. The most
relevant validated examples are summarized in Table 1B
[9,51,72,73,97]. For example, high-resolution array-CGH proﬁling
of progenitor cell derived murine HCCs of the genotype c-MYC;
P53/, revealed that these tumors spontaneously acquire geno-
mic ampliﬁcation of the 9qA1 chromosomal region, which is syn-
tenic to the human 11q22 region. Interestingly, this region has
been found ampliﬁed in different human tumors. Delineation of
the minimal region of overlap between human and mouse HCCs
and subsequent analyses of expression levels for all genes
embedded in the overlapping region, pinpointed cIAP1 and YAP
as potential driver genes of the 11q22 amplicon in human HCC.
Interestingly, when both genes were functionally tested in the
mouse model, they did not only accelerate hepatocarcinogenesis
individually, but also showed a strong collaboration to accelerate
the development of liver tumors. Therefore, these genes were val-
idated as new oncogenes in HCC and were found to be co-driver
genes of the 11q22 amplicon [98]. Importantly, a subsequent
study reported the expression of the YAP oncogene as an inde-
pendent prognostic factor in human HCC [98].0 vol. 52 j 921–929 925
Table 1. Relevant oncogenes and tumor suppressor genes identiﬁed through (A) selective dysregulation in animal models, or through (B) functional oncogenomic
approaches.
Gene name Oncogene/Tumor suppressor gene Biological activity/Pathway Reference
A) Long established HCC cancer genes which have been functionally validated in vivo
MYC Oncogene Proliferation control [12,71–73]
EGF Oncogene EGFR signaling (mitogenic signaling) [78]
TGFA Oncogene EGFR signaling (mitogenic signaling) [12,77]
CTNNB1 Oncogene Wnt-signaling [75,79]
APC Tumor suppressor gene Wnt-signaling [74,80]
PTEN Tumor suppressor gene PI3K/Akt/mTOR signaling [76,80]
AKT Oncogene PI3K/Akt/mTOR signaling [73]
HGF* Oncogene Growth factor [81,82]
MET Oncogene Growth factor receptor [83,84]
PDGFR Oncogene Growth factor receptor [60]
RAS (NRAS; HRAS) Oncogene Ras/MAPK signaling [71,73,75,85]
P53 Tumor suppressor gene Stress response, cell cycle inhibition [73,86]
E2F1 Oncogene Cell cycle [87]
CCND1 Oncogene Cell cycle [88,89]
Telomerase Oncogene Cell senescence [90]
B) HCC cancer genes recently identiﬁed and validated through integrative functional genomics
YAP Oncogene Hippo signaling pathway [73,97]
cIAP1 (BIRC2) Oncogene Regulation of cell death [73]
XPO4 Tumor suppressor gene Nuclear transport [80]
SET* Tumor suppressor gene/oncogene Histone chaperone [80]
NRSN2 Tumor suppressor gene Largely unknown [80]
GJD4 (CX40.1) Tumor suppressor gene Gap junction protein [80]
DDX20 Tumor suppressor gene RNA helicase [80]
FGF6 Tumor suppressor gene Fibroblast growth factor family [80]
FSTL5 Tumor suppressor gene Follistatin like protein [80]
ZBBX (FLJ23049) Tumor suppressor gene Largely unknown [80]
GLO1 Tumor suppressor gene Metabolism [80]
BTBD9 Tumor suppressor gene Largely unknown [80]
EIF5A2 Oncogene Translation control, mRNA-stability [80]
UBE2H** Oncogene Ubiquitylation [9]
EGFR Oncogene EGFR signaling (mitogenic signaling) [9]
AEG1 Oncogene WNT and NF-Kb signaling [51]
VEGF Oncogene Angiogenesis [6]
* Dual role, context-dependent activity has been suggested.
** Only in vitro validation.
ReviewThe discovery of RNA-interference has revolutionized ‘‘loss of
function genetics”. RNAi-based delivery strategies have shown
antitumoral activity in animal models of HCC [99], and dysregu-
lation of miRNA have also proved high prognostic predictive
value in this disease [100]. It was recently shown that stable RNAi
can be efﬁciently used in mosaic cancer mouse models
[73,80,101]. For example, the use of stable RNAi in murine
hepatocarcinomas that bore the cIAP1 and YAP embedding
9qA1 amplicon quickly allowed the validation of these genes as
promising therapeutic targets in HCC [73]. As microRNA- based
shRNAs can be driven by polymerase II promoters, available sys-
tems for tetracycline regulated gene expression can be combined
with this technology. This allows to reversibly regulate gene
expression in vivo. The use of reversible RNAi against the P53
tumor suppressor has recently enabled the identiﬁcation of P53
loss as a major requirement for the maintenance of murine liver
carcinomas [89]. Similar RNAi-based approaches were recently
used to functionally validate DLC-1 as a bona ﬁde tumor suppres-
sor included in 8p, a chromosomal region that is found deleted in
up to 50% of human HCC [102].
Importantly, RNAi technology cannot only be used on a single
gene level, but genome wide collections of siRNAs, shRNAs and
shRNAmir are available and have been successfully used for the
identiﬁcation of unbiased and comprehensive collections of
new gene targets in different biological systems [80]. Impor-
tantly, the feasibility of performing multiplex RNAi screens
in vivo was recently demonstrated [80]. In this study, an oncoge-926 Journal of Hepatology 201nomics-based shRNAmir library was generated by compiling
shRNAs against all genes that were found embedded in focal
deletions [<5 MB] of 98 human HCCs. A total of 362 candidate
tumor suppressor genes were found and corresponding mouse
orthologs for 301 of them were identiﬁed. More than 630
microRNAs against these genes were available in the Codex
shRNAmir library [http://codex.cshl.edu/scripts/newmain.pl]
and these hairpins were screened in the above described mosaic
liver cancer mouse model for their ability to accelerate tumorige-
nicity of immortalized liver progenitor cells of the background
MYC; P53/. This integrated approach proved highly effective,
resulting in the identiﬁcation and functional validation of 13
new tumor suppressor genes.
The top-scoring candidate tumor suppressor from the screen,
exportin 4, mediates the nuclear export of SMAD3, EIF5A1, and
EIF5A2. XPO4 loss seems to be pro-tumorigenic by promoting
the nuclear accumulation of its key substrates. Interestingly,
XPO4 deletions are relatively common, thus suggesting that this
may be an important mechanism of oncogenesis. It was observed
that suppression of XPO4 stimulates TGF-b signaling [80], which
can promote invasion and metastasis in late stage liver cancer.
Similarly, EIF5A2 over-expression occurs in many tumor types
[103] and it could be demonstrated that XPO4 loss enhances pro-
liferation through EIF5A2, which is per se oncogenic in mice [80].
Importantly, the XPO4-EIF5A2 signaling circuit appears relevant
in HCC and other tumor types.0 vol. 52 j 921–929
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ig. 2. Integrative oncogenomic strategies for accelerated cancer gene
iscovery in hepatocellular carcinoma. Schematic representation of functional
ncogenomics based strategies for the discovery of candidate genes involved in
CC pathogenesis.
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It is noteworthy that most of the identiﬁed genes have never
been linked to cancer before. Examples for identiﬁed genes are an
FGF (FGF6), an RNA helicase (DDX20/GEMIN3), a metabolic
enzyme (GLO1), and GJD4 (CX40.1), a gap junction protein. Func-
tional validation assays show that apparently all these genes act
as tumor suppressors in vivo. Some of the genes, for example
FSTL5, NRSN2 (C20ORF98), and ZBBX (FLJ23049), are largely
uncharacterized, however, based on the functional data obtained
from the mouse model and on the notion that all of them were
found somatically altered in human cancer, these genes very
likely represent important tumor suppressor genes in HCC. It is
obvious that more work will be required to understand how each
of these genes suppresses tumorigenesis, and, given the unex-
pected nature of each gene, such studies may uncover new path-
ways or principles relevant to human HCC. Some of the identiﬁed
genes point towards new strategies for cancer therapy. For exam-
ple, FGF6 and FSTL5 encode secreted proteins whose systemic
administration might restore tumor suppressor function and
serve as new biological anti-cancer therapies.
The described results establish the feasibility of performing
functional in vivo RNAi screens and illustrate how combining can-
cer genomics, RNAi and mosaic mouse models can facilitate the
functional annotation of the cancer genome (Fig. 2). Such integra-
tive approaches may complement existing large-scale approaches
like the human cancer genome project. Another appealing exam-
ple for in vivo screening approach to identify new cancer genes in
HCC was recently demonstrated by Keng et al. [9]. In their study
the authors used a liver directed insertional mutagenesis screen,
which was accomplished by hepatocyte-speciﬁc expression of a
mutagenic transposon to screen for new cancer genes in HCC.
This screen was performed either in a wild type or in a sensitized
background with a mutant p53 allele. In both backgrounds, pre-
neoplastic nodules could be detected starting 160 days after
liver-speciﬁc activation of the mutagenic transposon. The vast
majority of animals only contained pre-neoplastic nodules or
hepatic adenomas, but in some animals [>440 days of age] also
full-blown liver carcinomas were found. Using pyrosequencing,
the authors identiﬁed common insertion sites in the genomic
DNA from enucleated pre-neoplastic foci. A total of 19 common
insertion sites were identiﬁed and two affected genes were cho-
sen for functional validation, UBE2H and a truncated EGFR. While
deﬁnite experimental evidence that these genes cause HCC is still
missing, the authors were able to show that over-expression of
the candidate oncogene UBE2H accelerates proliferation of mur-
ine hepatoma cell line in vitro. The truncated EGFR was function-
ally tested resulting in the development of pre-neoplastic lesions
in re-populated mouse livers. While the long latency until tumor
development and the low penetrance to full blown HCC certainly
represent limitations of the model, it is yet noteworthy that some
of the 19 candidate HCC cancer genes could be found altered in
recently published datasets of human HCC. Therefore, it will be
of high interest to subject these candidate genes to thorough
functional validation in different HCC mouse models to ulti-
mately probe their contribution to the development of HCC.
With the advent of novel high-throughput technologies, such
as deep sequencing and integrative genomic analysis, and the con-
solidation of sophisticated animal models, such as mosaic cancer
mouse models or the use of transposons for mutagenic screening,
we are at the dawn of a new era in cancer gene discovery. These
technologies are identifying novel oncogenes and tumor suppres-
sor genes, which along with the already known drivers obtainedJournal of Hepatology 201F
d
o
Hfrom classical GEMM (Table 1) will provide amore comprehensive
picture of the key molecular alterations of liver cancer.Conﬂicts of interest
The Authors who have taken part in this study have declared a
relationship with the manufacturers of the drugs involved. Josep
Llovet has grants from the National Institute of Health -NIDDK
1R01DK076986-01, National Institute of Health (Spain) grant
I+D Program (SAF-2007-61898) and Samuel Waxman Cancer
Research Foundation, and the HCC Consortium are recipients of
the AACR-Landon Innovator International award. Dr Llovet has
consultancy agreements with Bayer Healthcare, BMS, Biocompa-
tibles, and is currently receiving funding for research from Bayer
Healthcare, BMS and Johnson & Johnson.
Lars Zender is supported by grants from the German Research
Foundation [Emmy Noether Programme] and grants from the
Helmholtz Association of German Research Centers (‘‘Helmholtz
Impuls und Vernetzungsfond”). Augusto Villanueva is supported
by a EASL-Sheila Sherlock Fellowship.
References
[1] Llovet J, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:
1907–1917.
[2] Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and
signaling pathways in hepatocellular carcinoma. Semin Liver Dis
2007;27:55–76.
[3] Llovet J, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design
and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer
Inst 2008;100:698–711.
[4] Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in
advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
[5] Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal
role of mTOR signaling in hepatocellular carcinoma. Gastroenterology
2008;135:1972–1983, 83 e1–e11.0 vol. 52 j 921–929 927
Review
[6] Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal
gains of VEGFA and molecular classiﬁcation of hepatocellular carcinoma.
Cancer Res 2008;68:6779–6788.
[7] Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al.
Epidermal growth factor gene functional polymorphism and the risk of
hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53–60.
[8] Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al.
Gene expression in ﬁxed tissues and outcome in hepatocellular carcinoma.
N Engl J Med 2008;359:1995–2004.
[9] Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, et al. A
conditional transposon-based insertional mutagenesis screen for genes
associated with mouse hepatocellular carcinoma. Nat Biotechnol
2009;27:264–274.
[10] Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C,
et al. Geﬁtinib, an EGFR inhibitor, prevents hepatocellular carcinoma
development in the rat liver with cirrhosis. Hepatology 2005;41:307–314.
[11] Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor
signaling in human hepatocellular carcinoma. Oncogene
2006;25:3787–3800.
[12] Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS.
Transgenic mouse model for synergistic effects of nuclear oncogenes and
growth factors in tumorigenesis: interaction of c-myc and transforming
growth factor alpha in hepatic oncogenesis 1. Cancer Res
1993;53:1719–1723.
[13] Philip P. Phase II study of erlotinib (OSI-774) in patients with advanced
hepatocellular cancer. J Clin Oncol 2005;23:6657–6663.
[14] Thomas M, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2
study of erlotinib in patients with unresectable hepatocellular carcinoma.
Cancer 2007;110:1059–1067.
[15] Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat
Rev Cancer 2008;8:915–928.
[16] Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a
potential cancer therapy. Mol Cancer Ther 2007;6:1–12.
[17] Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G. Hypomethylated P4
promoter induces expression of the insulin-like growth factor-II gene in
hepatocellular carcinoma in a Chinese population. Clin Cancer Res
2006;12:4171–4177.
[18] De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R
gene is mutated in human hepatocellular carcinomas with loss of
heterozygosity. Nat Genet 1995;11:447–449.
[19] Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, et al.
Reduced expression of insulin-like growth factor binding protein-3 and its
promoter hypermethylation in human hepatocellular carcinoma. Cancer
Lett 2002;176:149–158.
[20] Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang D, Sole M, et al. IGF
activation in a molecular subclass of hepatocellular carcinoma and pre-
clinical efﬁcacy of IGF-1R blockage. J Hepatol 2010;52:550–559.
[21] Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth
factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines:
implications of IGF-I receptor gene activation by hepatitis B virus X gene
product. Cancer Res 1996;56:3831–3836.
[22] Takayama H, Larochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, et al.
Diverse tumorigenesis associated with aberrant development in mice
overexpressing hepatocyte growth factor/scatter factor. PNAS 1997;94:
701–706.
[23] Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer
cell lines harboring MET gene ampliﬁcation are dependent on Met for
growth and survival. Cancer Res 2007;67:2081–2088.
[24] Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhib-
itors: targeting oncogene addiction and expedience. Nat Rev Drug Discov
2008;7:504–516.
[25] Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of
hepatocyte growth factor and its receptor c-met proto-oncogene in
hepatocellular carcinoma. Hepatology 1997;25:862–866.
[26] Kaposi-Novak P. Met-regulated expression signature deﬁnes a subset of
human hepatocellular carcinomas with poor prognosis and aggressive
phenotype. J Clin Invest 2006;116:1582–1595.
[27] Salvi A, Arici B, Portolani N, Giulini SM, De PG, Barlati S. In vitro c-met
inhibition by antisense RNA and plasmid-based RNAi down-modulates
migration and invasion of hepatocellular carcinoma cells. Int J Oncol
2007;31:451–460.
[28] Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways med-
iated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911–1912.
[29] Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the
mouse. Curr Opin Genet Dev 2009;19:4–11.928 Journal of Hepatology 201[30] Calvisi D, Ladu S, Gorden A, Farina M, Conner E, Lee J, et al. Ubiquitous
activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology
2006;130:1117–1128.
[31] Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L,
et al. Ras pathway activation in hepatocellular carcinoma and anti-
tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol
2009;51:725–733.
[32] Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphor-
ylation is a risk factor for early disease recurrence and poor prognosis in
hepatocellular carcinoma. Cancer 2005;103:307–312.
[33] Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway.
Curr Opin Cell Biol 2005;17:596–603.
[34] Sabatini DM. MTOR and cancer: insights into a complex relationship. Nat
Rev Cancer 2006;6:729–734.
[35] Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. MTOR
complex 2 is required for the development of prostate cancer induced by
Pten loss in mice. Cancer Cell 2009;15:148–159.
[36] Treiber G. MTOR inhibitors for hepatocellular cancer: a forward-moving
target. Expert Rev Anticancer Ther 2009;9:247–261.
[37] Yang Z. Signiﬁcance of CD90+ cancer stem cells in human liver cancer.
Cancer Cell 2008;13:153–166.
[38] Gonzalez C. Spindle orientation, asymmetric division and tumour suppres-
sion in Drosophila stem cells. Nat Rev Genet 2007;8:462–472.
[39] Zaret K. Genetic programming of liver and pancreas progenitors: lessons for
stem-cell differentiation. Nat Rev Genet 2008;9:329–340.
[40] Zaret K, Grompe M. Generation and regeneration of cells of the liver and
pancreas. Science 2008;322:1490–1494.
[41] Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and
disease. Hepatology 2007;45:1298–1305.
[42] Boyault S, Rickman DS, de RA, Balabaud C, Rebouissou S, Jeannot E, et al.
Transcriptome classiﬁcation of HCC is related to gene alterations and to
new therapeutic targets. Hepatology 2007;45:42–52.
[43] Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al.
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature
2009;461:614–620.
[44] Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, et al.
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis.
Carcinogenesis 2006;27:748–757.
[45] Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, et al. Down-
regulation of hedgehog-interacting protein through genetic and epigenetic
alterations in human hepatocellular carcinoma. Clin Cancer Res
2008;14:3768–3776.
[46] Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al.
Incidence of hepatocellular carcinoma and associated risk factors in
hepatitis C-related advanced liver disease. Gastroenterology
2009;136:138–148.
[47] Naugler W, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy A, et al. Gender
disparity in liver cancer due to sex differences in MyD88-dependent IL-6
production. Science 2007;317:121–124.
[48] Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, et al. The
STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with
disrupted TGF-beta signaling. Oncogene 2009;28:961–972.
[49] Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta
gene expression signature in mouse hepatocytes predicts clinical outcome
in human cancer. Hepatology 2008;47:2059–2067.
[50] Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inﬂam-
mation-ﬁbrosis-cancer axis. Hepatology 2007;46:590–597.
[51] Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, et al.
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development
and progression. J Clin Invest 2009;119:465–477.
[52] Haybaeck J, Zeller N, Wolf MK, Weber A, Wagner U, Kurrer MO, et al. A
lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell
2009;16:272–273.
[53] Villanueva A, Savic R, Llovet JM. Lymphotoxins: novel targets for HCC.
Cancer Cell 2009;16:272–273.
[54] Li XM, Tang ZY, Zhou G, Lui YK, Ye SL. Signiﬁcance of vascular endothelial
growth factor mRNA expression in invasion and metastasis of hepatocel-
lular carcinoma. J Exp Clin Cancer Res 1998;17:13–17.
[55] Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic signiﬁcance of
serum vascular endothelial growth factor and endostatin in patients with
hepatocellular carcinoma. Br J Surg 2004;91:1354–1360.
[56] Imura S, Miyake H, Izumi K, Tashiro S, Uehara H. Correlation of vascular
endothelial cell proliferation with microvessel density and expression of
vascular endothelial growth factor and basic ﬁbroblast growth factor in
hepatocellular carcinoma. J Med Invest 2004;51:202–209.0 vol. 52 j 921–929
JOURNAL OF HEPATOLOGY
[57] Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al.
Synergistic effect of basic ﬁbroblast growth factor and vascular endothelial
growth factor in murine hepatocellular carcinoma. Hepatology
2002;35:834–842.
[58] Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, et al.
Angiopoietins and Tie-2 expression in angiogenesis and proliferation of
human hepatocellular carcinoma. Hepatology 2003;37:1105–1113.
[59] Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ,
et al. Targeting stromal cells for the treatment of platelet-derived growth
factor C-induced hepatocellular carcinogenesis. Differentiation
2007;75:843–852.
[60] Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC,
et al. Platelet-derived growth factor C induces liver ﬁbrosis, steatosis, and
hepatocellular carcinoma. PNAS 2005;102:3389–3394.
[61] Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature
2004;432:307–315.
[62] Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of
p53 mutational proﬁle in nonmalignant human liver. Science
1994;264:1317–1319.
[63] Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric
oxide-induced cellular stress and p53 activation in chronic inﬂammation.
PNAS 2003;100:143–148.
[64] Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver
carcinogenesis. Hum Mutat 2003;21:201–216.
[65] Velculescu VE. Deﬁning the blueprint of the cancer genome. Carcinogenesis
2008;29:1087–1091.
[66] Chin L, Gray JW. Translating insights from the cancer genome into clinical
practice. Nature 2008;452:553–563.
[67] Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al.
Patterns of somatic mutation in human cancer genomes. Nature
2007;446:153–158.
[68] Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic
landscapes of human breast and colorectal cancers. Science
2007;318:1108–1113.
[69] Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and
challenges. Cell 2002;108:135–144.
[70] Sharpless N, Depinho R. The mighty mouse: genetically engineered mouse
models in cancer drug development. Nat Rev Drug Discov 2006;5:741–754.
[71] Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-
induced liver neoplasia in transgenic mice. Oncogene 1989;4:715–724.
[72] Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al.
MYC inactivation uncovers pluripotent differentiation and tumour dor-
mancy in hepatocellular cancer. Nature 2004;431:1112–1117.
[73] Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al.
Identiﬁcation and validation of oncogenes in liver cancer using an
integrative oncogenomic approach. Cell 2006;125:1253–1267.
[74] Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, et al.
Liver-targeted disruption of Apc in mice activates beta-catenin signaling
and leads to hepatocellular carcinomas. PNAS 2004;101:17216–17221.
[75] Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM.
Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene muta-
tions. Cancer Res 2004;64:48–54.
[76] Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-
speciﬁc Pten deﬁciency results in steatohepatitis and hepatocellular
carcinomas. J Clin Invest 2004;113:1774–1783.
[77] Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGF alpha
overexpression in transgenic mice induces liver neoplasia and abnormal
development of the mammary gland and pancreas. Cell 1990;61:
1137–1146.
[78] Tonjes RR, Lohler J, O’Sullivan JF, Kay GF, Schmidt GH, Dalemans W, et al.
Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus
during hepatocarcinogenesis in transgenic mice. Oncogene 1995;10:
765–768.
[79] Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct
pathways of genomic progression to benign and malignant tumors of the
liver. PNAS 2007;104:14771–14776.
[80] Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An
oncogenomics-based in vivo RNAi screen identiﬁes tumor suppressors in
liver cancer. Cell 2008;135:852–864.
[81] Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, et al.
Hepatocyte growth factor promotes hepatocarcinogenesis through c-MetJournal of Hepatology 201autocrine activation and enhanced angiogenesis in transgenic mice treated
with diethylnitrosamine. Oncogene 2002;21:1791–1799.
[82] Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ.
Hepatocyte growth factor/scatter factor overexpression induces growth,
abnormal development, and tumor formation in transgenic mouse livers.
Cell Growth Differ 1996;7:1513–1523.
[83] Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic
progression in mouse models for liver tumors. Cold Spring Harb Symp
Quant Biol 2005;70:217–224.
[84] Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met
receptor by cell attachment induces and sustains hepatocellular carcino-
mas in transgenic mice. J Cell Biol 2001;153:1023–1034.
[85] Carlson CM, Frandsen JL, Kirchhof N, McIvor RS, Largaespada DA.
Somatic integration of an oncogene-harboring Sleeping Beauty transpo-
son models liver tumor development in the mouse. PNAS 2005;102:
17059–17064.
[86] Klocke R, Bartels T, Jennings G, Brand K, Halter R, Strauss M, et al. Lack of
p53 accelerates hepatocarcinogenesis in transgenic mice constitutively
overexpressing c-myc in the liver. FASEB J 2001;15:1404–1406.
[87] Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS.
Dual functions of E2F-1 in a transgenic mouse model of liver carcinogen-
esis. Oncogene 2000;19:5054–5062.
[88] Deane NG, Lee H, Hamaamen J, Ruley A, Washington MK, LaFleur B, et al.
Enhanced tumor formation in cyclin D1  transforming growth factor
beta1 double transgenic mice with characterization by magnetic resonance
imaging. Cancer Res 2004;64:1315–1322.
[89] Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, et al.
Hepatocellular carcinoma results from chronic cyclin D1 overexpression in
transgenic mice. Cancer Res 2001;61:5389–5395.
[90] Farazi P, Depinho R. Hepatocellular carcinoma pathogenesis: from genes to
environment. Nat Rev Cancer 2006;6:674–687.
[91] Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental
models of hepatocellular carcinoma. J Hepatol 2008;48:858–879.
[92] Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo
C, et al. Evasion of the p53 tumour surveillance network by tumour-derived
MYC mutants. Nature 2005;436:807–811.
[93] Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, et al. Efﬁcient and
rapid induction of a chronic myelogenous leukemia-like myeloproliferative
disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood
1998;92:3780–3792.
[94] Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW.
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell
2002;1:289–298.
[95] Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A
senescence program controlled by p53 and p16INK4a contributes to the
outcome of cancer therapy. Cell 2002;109:335–346.
[96] Zender L, Xue W, Cordon-Cardo C, Hannon GJ, Lucito R, Powers S, et al.
Generation and analysis of genetically deﬁned liver carcinomas derived
from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol
2005;70:251–261.
[97] Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1
increases organ size and expands undifferentiated progenitor cells. Curr
Biol 2007;17:2054–2060.
[98] Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated
protein is an independent prognostic marker in hepatocellular carcinoma.
Cancer 2009;19:4576–4585.
[99] Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang
HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a
murine liver cancer model. Cell 2009;137:1005–1017.
[100] Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression,
survival, and response to interferon in liver cancer. N Engl J Med
2009;361:1437–1447.
[101] Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-
Cardo C, et al. An epi-allelic series of p53 hypomorphs created by stable
RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003;33:
396–400.
[102] Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, et al.
DLC1 is a chromosome 8p tumor suppressor whose loss promotes
hepatocellular carcinoma. Genes Dev 2008;22:1439–1444.
[103] Clement PM, Johansson HE, Wolff EC, Park MH. Differential expression of
eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 2006;273:1102–1114.0 vol. 52 j 921–929 929
